Search Within

Michael Morris

Formats
  1. Meeting Abstract (275)
  2. Journal Article (268)
  3. Review (20)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (586)
  2. Genitourinary Oncology Service (586)
  3. Solid Tumor Oncology Division (586)
  4. Radiology, Department of (164)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (141)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (27)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (44)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (44)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (586)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PSMA-targeted imaging with (18)F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Josephson, D.; Carroll, P. R.; Wong, J. Y. C.; Pantel, A. R.; Cho, S. Y.; Gage, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A prospective phase 2/3 study of PSMA-targeted (18)F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging
    Meeting Abstract

    Durack, J. C.; Alva, A. S.; Preston, M. A.; Pouliot, F.; Saperstein, L.; Carroll, P. R.; Pienta, K. J.; Rowe, S. P.; Patnaik, A.; Probst, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801)
    Meeting Abstract

    McKay, R. R.; Jacene, H.; Atherton, P. J.; Burbano, G. P.; Ajmera, A.; Baghaie, S.; Koball, J.; Zemla, T. J.; Chen, R. C.; Choudhury, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA
    Meeting Abstract

    Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.; Hamberg, P.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing
    Meeting Abstract

    Truong, H.; Breen, K.; Kemel, Y.; Lenis, A. T.; Reisz, P.; Benfante, N.; Ehdaie, B.; Touijer, K. A.; Laudone, V. P.; Scardino, P. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)
    Journal Article

    Pienta, K. J.; Gorin, M. A.; Rowe, S. P.; Carroll, P. R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M. A.; Alva, A. S.; Patnaik, A.; more...
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: A single-center retrospective cohort study
    Journal Article

    Wibmer, A. G.; Morris, M. J.; Gonen, M.; Zheng, J.; Hricak, H.; Larson, S.; Scher, H. I.; Vargas, H. A.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19
    Journal Article

    Schmidt, A. L.; Tucker, M. D.; Bakouny, Z.; Labaki, C.; Hsu, C. Y.; Shyr, Y.; Armstrong, A. J.; Beer, T. M.; Bijjula, R. R.; Bilen, M. A.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)
    Meeting Abstract

    Morris, M. J.; De Bono, J. S.; Chi, K. N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Nordquist, L. T.; Vaishampayan, N.; El-Haddad, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save